Jubilant Life falls 6% as USFDA recommends action on failing inspection

The stock dipped 6% to Rs 742 on the BSE after the US health regulator recommended a regulatory or administrative action after the inspection of the drug firm's Roorkee manufacturing facility.

Shares of Jubilant Life Sciences have dipped 6% to Rs 742 per share on the BSE in early morning trade after the US health regulator recommended a regulatory or administrative action after the inspection of the drug firm's Roorkee manufacturing facility.

“In response to the US Food & Drug Administration (USFDA) inspection conducted at its Roorkee facility of solid dosage formulations during August 2018, the agency has informed to classify the inspection as “Official Action Indicated” (OAI) and that approvals of pending applications or supplements from this site maybe withheld,” Jubilant Life Sciences said in a regulatory filing on Saturday, December